Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia

NCT03631576 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT03631576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03631576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
Lead sponsor
Fujian Medical University
Phase
Phase 2/3
Overall status
Unknown status
Start date
August 10, 2018
Completion date
August 10, 2021
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory aml